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Abstract
Objectives Reproductive malfunctions after chemotherapy still are a reason of
reducing fertility and need specialized intensive care. The aim of this review was
to investigate the effect of melatonin on the reproductive system under threaten-
ing with chemotherapeutic drugs.
Methods To find the role of melatonin in the reproductive system during
chemotherapy, a full systematic literature search was carried out based on Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines in
the electronic databases up to 17 April 2017 using search terms in the titles and
abstracts. A total of 380 articles are screened according to our inclusion and
exclusion criteria. Finally, 18 articles were included in this study.
Key findings It has been cleared that melatonin has bilateral effects on reproduc-
tive cells. Melatonin protects normal cells via mechanisms, including decrease in
oxidative stress, apoptosis, inflammation and modulating mitochondrial func-
tion, and sexual hormones. Furthermore, melatonin with antiproliferative prop-
erties and direct effects on its receptors improves reproductive injury and
function during chemotherapy. On the other hand, melatonin sensitizes the
effects of chemotherapeutic drugs and enhances chemotherapy-induced toxicity
in cancerous cells through increasing apoptosis, oxidative stress and mitochon-
drial malfunction.
Conclusions The study provides evidence of the bilateral role of melatonin in
the reproductive system during chemotherapy.
Introduction
Nowadays, cancer is one of the major prominent, which
affects every society. It causes many deaths worldwide.
From 12.7 million cases that cancer encompasses, 7.6 mil-
lion of them will probably face death in a year.[1] Many
investigations have focused on battling cancer with the
lowest adverse effects and have made it the most impor-
tant priority for researchers.[2] Although anticancer drugs
are more efficient, they all have adverse effects due to dele-
terious cytotoxicity against normal cells and tissues in
chemotherapy process.[3] The reproductive system is one
of the vulnerable organs to chemotherapy. The process of
chemotherapy may lead to alteration in fertility, changing
in organ structure, sexual hormones, and function and
quality of life.[4] Some techniques such as embryo cryop-
reservation, mature oocyte cryopreservation and ovarian
tissue cryopreservation can be applied prior to chemother-
apy process.[5] Moreover, these techniques have limita-
tions. They cannot be done in all centres and also, they are
invasive to patients.[6] In this regard, many researches are
ongoing to discover the effects of some protective agents
which can be used in combination with anticancer drugs
to mitigate deleterious side effects.[7–9] In this content,
using gonadoprotective agents may be useful as an option
to increase effectiveness of fertility preservation and repro-
ductive health in patients receiving chemotherapy.[3] Based
on the evidence, melatonin in combination with
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anticancer drugs has profits and reduces deleterious dam-
ages of chemotherapy in the reproductive system.[10,11]
Utilization of melatonin has been noticeably increased in
various diseases and different organs, indicating the pleio-
tropy of this molecule.[12] Melatonin, N-acetyl-5-methoxy-
tryptamine, is a lipophilic indoleamine which regulates a
variety of physiological functions in the body and numer-
ous reports have evidenced the protective effects of it
through multiple pathways on pathological situations.[13–15]
Melatonin and its metabolites including cyclic
3-Hydroxymelatonin (3-OHM), N1-acetyl-N2-formyl-5-
methoxykynuramine (AFMK) and N1-acetyl-5-methoxy-
kynuramine (AMK) were found as vigorous free radical
scavengers.[16] Melatonin directly exerts its antioxidant
effects through radical adduct formation, single electron
transfer and hydrogen transfer.[16,17] Moreover, mela-
tonin indirectly mitigates oxidative stress via upregula-
tion of antioxidant enzymes, downregulation of
pro-oxidant enzymes, as well as maintenance of mito-
chondrial homoeostasis, as the main source of reactive
oxidative species (ROS) production.[18,19] 3-OHM as an
immediate by-product has more antioxidant power com-
paring to its ancestor and other metabolites.[20] Mela-
tonin with non-enzymatic way is converted to AFMK and
is mainly produced in mitochondria because of its high
accumulation.[21] AMK via inhibiting nitric oxide syn-
thase (NOS) activity reduces nitric oxide (NO) both in
mitochondria and cytosol.[22] Previous studies demon-
strated that melatonin exerts its anti-apoptotic effects
through inhibition of mitochondrial permeability transi-
tion pore. This exertion results in reduction of releasing
factors including cytochrome C, Smac/DIABLO, and the
serine protease HtrA2/Omi, apoptosis-inducing factor,
endonuclease G and caspase-activated DNAse, which play
pivotal roles in triggering apoptosis.[23,24] NO induces
release of pro-apoptotic calcium, from mitochondria to
cytoplasm. Melatonin, through reducing expression of
inducible nitric oxide synthase (iNOS), reduces NO
levels.[25–27] Many reports have also shown that mela-
tonin regulates Sertoli cells metabolism during gametes
development. Melatonin, due to its amphiphilic proper-
ties, acts peripherally through binding to intracellular
proteins, nuclear receptors and membrane melatonin
receptors including MT1 and MT2.[28] In this regard,
melatonin and melatonin receptors act via affecting the
secretion of both gonadotropin-releasing hormone and
luteinizing hormone (LH) gonadotropins, and testosterone
synthesis as well as testicular maturation. Thus, it can
improve reproductive function quality.[29] Also, mammalian
gametes and embryos are highly vulnerable to oxidative
stress due to the presence of high lipid levels. In this case,
melatonin prevents reproductive damages through its
potent antioxidant and anti-apoptotic ability.[30]
To the best of our knowledge, this is the first systematic
review on the protective/sensitizing role of melatonin as a
combination therapy in chemotherapy-induced reproduc-
tive toxicity. In this content, these questions will be risen:
How chemotherapy process destroys the reproductive sys-
tem? What is the role of melatonin on reproductive toxicity
induced by chemotherapy? And what are the mechanisms
of this role? In order to make a comprehensive vision of
melatonin effects on reproductive cells during chemother-
apy process and to answer to the above questions, we aimed
to discuss the harmful effects of anticancer drugs on the
reproductive system and the mechanisms through which
melatonin exerts its role. So, we criticized all studies used
melatonin as a combination on reproductive cells following
by chemotherapy.
Methods
Search strategy
This systematic review was designed according to the
guidelines of the 2009 Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines.[31] Literature search was performed to identify all
available studies in the electronic databases, including
PubMed, Web of Science, Scopus and EMBASE up to
17 April 2017, using the following search terms in the
titles and abstracts: (melatonin) and (testes or testicular
or reproductive or sperm or ovarian or follicle) and
(doxorubicin or daunorubicin or idarubicin or cisplatin
or carboplatin or oxaliplatin or bleomycin or car-
mustine or cyclophosphamide or melphalan or etopo-
side or mitomycin or vinblastine or vinorelbine or
paclitaxel or docetaxel or procarbazine or epirubicin or
methotrexate or mustine or cytarabine or 5-fluorouracil
or capecitabine).
Study selection
Original articles were included that met the following
inclusion criteria: (1) studies that used a combination of
melatonin and others search term; (2) studies with full-text
articles; (3) studies with sufficient information; and (4) no
limitation in publications with in-vivo or in-vitro subjects.
Exclusion criteria included as follows: (1) case report, (2)
letter to the editor, (3) not related abstracts, (4) incomplete
data on effects of melatonin on the reproductive system
and (5) review articles.
Data extraction
Each eligible article was reviewed and the following infor-
mation including: (1) authors’ names; (2) type of
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reproductive injury; (3) models; (4) chemical and dosage as
well as route of administration; (5) melatonin dosage and
route of administration; (6) chemical outcomes; and (7)
melatonin co-administration outcomes were extracted. The
extracted data and characteristics of the 18 included studies
were summarized in Table 1.
Results
Literature search
Our initial search on multiple databases up to 17 April
2017 resulted in a total of 380 published. Of these, 337 arti-
cles were excluded after the title and abstract screening
because they did not meet our inclusion criteria. Thus, 43
full-text articles were eligible for full-text assessed and
reviewed. Twenty-five articles were eliminated because for
non-original article (n = 3), incompatible data (n = 6), not
related studies (n = 16). Eventually, 18 remaining articles
were included in the systematic review. The study selection
process is described in Figure 1.
Protective effects of melatonin from
toxicity of chemotherapeutic drugs
Cyclophosphamide (Cytoxan) is a chemotherapeutic alky-
lating drug, widely used as a medication for its antitumour
and immunosuppressant properties.[32] Cyclophosphamide
is bioactivated through hepatic microsomal cytochrome
P450, and these metabolites are responsible for therapeutic
activity. It has been also shown that cyclophosphamide has
a wide range of side effects such as testicular toxicity.[33–35]
In a study, cyclophosphamide increased lipid peroxidation
(LPO) and malondialdehyde (MDA) levels, and reduced
catalase (CAT), superoxide dismutase (SOD) and glu-
tathione peroxidase (GSH-Px) activity as well as glu-
tathione (GSH) level in the testis. Co-administration with
melatonin reduced the levels of MDA, thiobarbituric acid
reactive substances, and also increased SOD and CAT activ-
ity as well as GSH levels.[36,37] Moreover, body and testicu-
lar weights were significantly reduced by
cyclophosphamide.[37,38] Co-administration of melatonin
preserved testicular weight.[37] In histopathological studies,
cyclophosphamide induced maturation arrest and deple-
tion in sperms ancestors, congested blood vessels and
decreased seminiferous epithelial layers, as well as irregular
and diminished tubules containing a few germ cells.[36,37,39]
Cyclophosphamide significantly decreased the sperm count
and percentage of motile sperms, whereas a significant
increase was observed in the percentage of abnormal
sperms in rats treated with cyclophosphamide.[37] Co-treat-
ment of melatonin and cyclophosphamide showed a signifi-
cant protection in spermatogenesis.[37] In addition,
cyclophosphamide induced a mild perivascular fibrosis and
hyalinization of intertubular tissues which were not
observed in the groups received melatonin and cyclophos-
phamide together.[37,39]
Cisplatin (cis-diamminedichloroplatinum-II) is a highly
effective chemotherapeutic drug which is used in various
cancers.[40] Cisplatin causes significant side effects on
peripheral nerves, head and neck, kidneys, lung, ovarian,
testes and myelosuppression.[41,42] Cisplatin treatment sig-
nificantly increased MDA and GSH levels, it also decreased
SOD, CAT and GSH-Px activity in testes.[37,43] Melatonin
co-administration decreased MDA, SOD and CAT levels
but increased GSH-Px activity and GSH levels.[44] Cis-
platin significantly reduced body weight, weight, and size
of testis, epididymis, seminal vesicle, prostate, and
ovary.[43,45] Co-administration with melatonin normalized
body weight, weights, and sizes of testes, epididymis, and
prostate.[45] In addition, cisplatin decreased sperm concen-
tration and motility, while abnormal sperms were
increased. Co-treatment with melatonin with cisplatin pro-
vided moderate normalization of sperm concentration.[44]
Cisplatin also induced severe degeneration, necrosis, and
interstitial oedema and decreased the diameter of the sem-
iniferous tubule and germinal cell thickness.[43] These
changes were partially reversed by treatment with mela-
tonin.[43] Melatonin co-administration with cisplatin and
vinblastine, as well as bleomycin, showed partial restora-
tion in different spermatogenic stages with intact basement
membrane and marginal increase.[44] Furthermore, cis-
platin induced a significant decrease in germ cells, seminif-
erous epithelial layers and spermatogonia, as well as
irregular seminiferous tubules, significant maturation
arrest and low Johnsen score in testis.[37] Perivascular
fibrosis and hyalinization of intertubular tissues were
observed in the rats receiving cisplatin, while melatonin
recovered these damages.[37] Moreover, cisplatin alone or
in combination with vinblastine and bleomycin decreased
plasma testosterone levels and increased follicle stimulating
hormone (FSH) and LH levels which is significantly nor-
malized by melatonin.[37,44] Furthermore, cisplatin
decreased 3b- and 17b-hydroxysteroid dehydrogenases
(HSDs) activity, as marker enzymes for steroidogenesis, in
combination with vinblastine and bleomycin. Co-adminis-
tration of melatonin resulted in significant increase in the
HSDs activity.[44] Also, cisplatin elevated abnormal multi
folliculogenesis and activated primary follicles, ovarian
abnormalities, atrophy, corpus luteum and reduced the
number of dormant primordial follicles in the ovary. Co-
administration of melatonin significantly improved ovar-
ian abnormalities, the number of primordial follicles and
it also suppressed primary follicle formation loss through
repressing the activation of primordial follicles into pri-
mary follicles.[45] Cisplatin induced apoptosis around the
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growing follicles and melatonin attenuated apoptosis.[45,46]
Moreover, cisplatin upregulated phosphorylation of PTEN
and FOXO3a.[45]
Doxorubicin (or Adriamycin) belongs to anthracycline
family and were firstly isolated from Streptomyces peuce-
tius.[46] Doxorubicin is mostly used to cure cancers
including stomach, lung, breast, bladder, thyroid, soft tis-
sue sarcoma, Hodgkin’s lymphoma, multiple myeloma
and mainly in ovaries.[47] Doxorubicin significantly
increased oxidative stress markers such as LPO, MDA
and GSH levels but decreased glutathione S-transferase
(GST), glutathione reductase (GR), CAT and SOD activ-
ity.[48] Melatonin with its antioxidant property normal-
ized level of MDA and activity of GST, GR and SOD as
well as GSH content. Also, CAT activity was slightly
higher in the doxorubicin in combination with melatonin
group compared to the doxorubicin group.[48] Further-
more, doxorubicin caused an elevation in serum levels of
glutamic oxaloacetate transaminase, creatine kinase and
lactate dehydrogenase, which is noticeably reduced by
melatonin.[48] Doxorubicin also significantly decreased
weights of body, testes and seminal vesicles.[48,49] Co-
administration of melatonin slightly improved body
weight.[49] In another study, co-administration of mela-
tonin with doxorubicin restored body and testes weight
compared to normal group.[48] Doxorubicin caused a lot
of injuries in testes tissue, including decrease in sper-
matogonia and early spermatocytes, as well as vacuolation
and fibrinoid debris; however, melatonin restored these
changes.[48,49] Doxorubicin significantly leads to reducing
the levels of membrane-bound enzymes like Ca2+ATPase,
Mg2+ATPase and Na+K+ATPase. It is shown that co-
administration of melatonin significantly normalized
these enzymes.[48]
Procarbazine is an anticancer drug used in the treat-
ment of Hodgkin’s lymphomas, multiple myeloma, brain
tumour, melanoma and lung cancer.[50] In the testes,
procarbazine caused a decrease in spermatogonia levels
and germinative layer diameter. These criteria were
increased by melatonin.[51] Also, morphology, localization
and maturation of germinative cells and Sertoli cells were
improved by melatonin group vs procarbazine group.[51]
Procarbazine significantly changed oxidative stress mark-
ers such as increasing levels of MDA and nitrite/nitrate
(NO2 /NO

3 ) as well as decreasing activity of GSH-Px.
On the other hand, activity of GSH-Px is reversed by
melatonin.[51]
Busulfan (butane-1,4-diyl dimethanesulfonate) is an
alkylating drug and used as an alleviating management in
malignant diseases, including polycythemia vera and
myeloproliferative disorders.[52] Busulfan is a very toxic
chemotherapy drug, which causes side effects in multiple
organs, including the reproductive system.[53,54] BusulfanTa
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induced disruption in seminiferous tubules structure,
degeneration in germinal cells and a significant decrease
in thickness of the seminiferous tubules in the testis.[53,55]
Melatonin co-administration attenuated these conse-
quences with its protective properties. Moreover, busulfan
reduced epididymal sperm motility and concentration
and also increased abnormal sperm rates.[55] Melatonin
co-administration increased sperm count and motility
and decreased rates of abnormal sperm. In addition,
busulfan increased apoptosis in germ cells and seminifer-
ous tubules.[53,55,56] On the other hand, melatonin co-
administration either significantly or non-significantly
decreased apoptosis in seminiferous tubules and germ
cells.[53,55,56] In addition, busulfan remarkably decreased
testosterone levels, which is normalized by melatonin.[55]
Busulfan causes oxidative stress via decreasing manganese
superoxide dismutase (MnSOD) expression and increas-
ing intracellular ROS, which is modulated by melatonin.
Furthermore, busulfan induced mitochondrial dysfunc-
tion. However, melatonin co-administration partially
decreased mitochondrial dysfunction.[56] Besides that,
busulfan induced apoptosis, consequently spermatogonia
loss via upregulation of caspase-3, downregulation of
Sirtuin type 1 (SIRT1) and increased extracellular
signal-regulated kinase (ERK) as well as p38 phosphoryla-
tion.[56] Co-administration of melatonin with busulfan
significantly increased SIRT1.[56] Busulfan significantly
destroyed ovarian follicles and mature atrophied follicles
while melatonin co-administration noticeably decreased
mature atrophied follicles.[57]
Effects of melatonin on sexual hormones
and receptors-mediated from toxicity of
chemotherapeutic drugs
Sexual hormones are related to sexual function, vitality and
physical function. Numerous reports have evidenced that
the chemotherapeutic drugs induce an alteration in sexual
hormones level. Cisplatin alone or in combination with
vinblastine, bleomycin, cyclophosphamide, doxorubicin
and procarbazine significantly reduced plasma level of
testosterone, whereas melatonin co-administration signifi-
cantly increased plasma testosterone level.[37,48,51] More-
over, cisplatin in combination with vinblastine and
bleomycin increased FSH and LH levels, while normalized
by melatonin.[44]
Chemosensitizing effects of melatonin from
toxicity of chemotherapeutic drugs
5-fluorouracil (5-FU) is an antimetabolite chemotropic
drug acts through two mechanisms including interfering
with DNA and RNA that results in production of macro-
molecules as well as inhibiting essential biosynthetic func-
tions.[58] 5-FU is widely used in the treatment of cancers,
including breast, colorectal, head and neck and aerodiges-
tive tract ones.[59] In a study, 5-FU significantly decreased
human cervical carcinoma (HeLa) cells viability compared
to the control group. Interestingly, co-administration of
5-FU with melatonin significantly increased 5-FU stimu-
lated cytotoxicity. Furthermore, treatment of HeLa cells
Figure 1 Flow diagram of the study selection process. [Colour figure can be viewed at wileyonlinelibrary.com]
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with 5-FU and melatonin elevated caspase-3 and caspase-9
activity as well as ROS generation compared to the 5-FU
group.[43]
Cisplatin decreased the viability of SK-OV-3 ovarian
cancer cells by 20%, and melatonin dose dependently
increased the viability of cells.[60] Cisplatin also increased
apoptosis in SK-OV-3 cells, whereas melatonin in combina-
tion with cisplatin synergistically increased apoptosis.[61] In
this regard, melatonin increased activation of caspase-3 and
cleavage of Poly-(ADP ribose) polymerase (PARP) induced
by cisplatin.[61] It is also shown that cisplatin prevents
phosphorylation of heat-shock protein 27 (HSP27), ERK
and phospho-90-kDa ribosomal S6 kinase (p90RSK),
whereas in synergistic manner melatonin with cisplatin
decreased phosphorylation of HSP27, ERK and p90RSK
compared to cisplatin group.[61] Cisplatin alone or in com-
bination with melatonin inhibited the expression and colo-
calization of HSP27 and p90RSK in SK-OV-3 cells
compared to the control or melatonin groups.[61] Further-
more, melatonin or cisplatin had no significant effect on
mitogen-activated protein kinase phosphatase 3 (MKP3)
levels but cisplatin in combination with melatonin signifi-
cantly increased MKP3 level.[61] In another study,
melatonin sensitized HeLa cells to cisplatin and doxoru-
bicin toxicity. Cisplatin and doxorubicin reduced HeLa
cells viability compared to the control group and interest-
ingly co-administration of melatonin significantly reduced
viability. Moreover, cisplatin increased caspase-3 and 9
activity, ROS generation and eventually apoptosis and
melatonin in combination with cisplatin elevated ROS gen-
eration, caspase-3 and 9 activity as well as apoptosis com-
pared to the cisplatin group.[60] Doxorubicin induced
increase in caspase-3 activity and melatonin in synergism
manner increased caspase-3 activity.[61]
Discussion
In this review, the impairments induced by cyclophos-
phamide, cisplatin, doxorubicin, procarbazine, busulfan
and 5-FU drugs on the reproductive system, as well as co-
administration effects of melatonin on these disorders were
evaluated. Furthermore, the chemosensitizing effect of
melatonin on SK-OV-3 and HeLa cells in concurrent treat-
ment with cisplatin was assessed. The important effects of
melatonin in normal and cancer cells are illustrated in
Figures 2 and 3.
Figure 2 Important effects of melatonin in normal cells. [Colour figure can be viewed at wileyonlinelibrary.com]
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Although chemotherapeutic regimes are highly effective in
the treatment of different malignancies, their clinical utility
is limited because of a wide range of side effects such as nau-
sea, vomiting, dysphoria, injury to kidney, lung, reproduc-
tive organs. The reproductive system includes some of the
external and internal organs that participate together for the
purpose such as vitality, physiological function and procreat-
ing. Because of its critical function in the survival of the spe-
cies, it has attracted the attention of many researchers. These
organs are extremely vulnerable to chemotherapy drugs,
because of their structures. The toxicity of these drugs in
reproductive systems is associated with variable factors, such
as the number of chemotherapeutic drugs, antineoplastic
drug group, treatment duration, their total doses and indi-
vidual sensitivity.[62,63] Using protective agents during
chemotherapy has been proposed as a possible solution to
reduce chemotherapeutic side effects. Co-administration of
melatonin during chemotherapy acts as a double-edged
sword on tumoral and normal organs/cells. In the other
words, in normal organs/cells, melatonin results in the
preservation of testicular epididymis, Sertoli cell, testes and
prostate weights, improve sperm count and modulates sex-
ual hormone levels through their antioxidant, anti-apopto-
tic, antiproliferative effects, etc. Furthermore, it has
chemosensitizing effects on tumoral cells through increasing
oxidative stress, apoptosis, etc.[32,37,39,43,48,49,51,53,55,64] In the
following paragraphs, various mechanisms of melatonin on
the reproductive system are discussed.
Antioxidant effects of melatonin
Oxidative stress is an imbalance between the biological
defences and generation of free radical agents. Increasing
the intracellular level of free radicals, as an oxidative stress
biomarker, indicates toxicity potential, which reacts with
cell macromolecules and cell dysfunctions.[65] The chief
property of antioxidants is the capacity to capture free radi-
cals. Recently, the role of melatonin as a high potent
antioxidant has attracted many attentions. The primary
protection mechanisms of melatonin seem to be under-
taken through both direct and indirect pathways.[66,67]
Melatonin in direct way scavenges the singlet oxygen, per-
oxyl radical, superoxide anion radical and peroxynitrite
anion.[68–70] Each melatonin molecule scavenges two
hydroxyls-free radical (OH).[70] In addition, melatonin is
capable of increasing the efficiency of mitochondrial elec-
tron transport and decreasing free radical generation and
electron leakage. Therefore, it is concluded that the capabil-
ity of melatonin as a direct free radical scavenger may be
due to its electron-donating potency.[71] Unlike well-
known antioxidants like vitamin E and C, which are exclu-
sively lipid and water-soluble respectively, melatonin has a
limited intracellular distribution. Because of the small size
and amphiphilic property melatonin can transit from cell
membrane easily so that it preserves macromolecules
against free radical induced injury in both aqueous subcel-
lular and lipid segments.[43,72] Moreover, it has been
reported that melatonin is five times more impressive in
scavenging hydroxyl radicals than glutathione.[73] In addi-
tion, melatonin metabolites have antioxidant effects too,
even more than their ancestor. Melatonin can decrease
non-enzymatic LPO in rat testicular mitochondria and
microsomes by changing both docosapentaenoic and
arachidonic acids.[74] It has been reported that the restora-
tion of membrane-bound enzymes like Mg2+ ATPase, Ca2+
ATPase and Na+ K+ ATPase in rats treated with melatonin
Figure 3 Important effects of melatonin in cancerous cells. [Colour figure can be viewed at wileyonlinelibrary.com]
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is due to the membrane stabilizing related to the protective
effect of melatonin.[75] Furthermore, it was shown that
melatonin can break the vicious cycle of ROS generation
and mitochondrial damage. In other words, it has an indi-
rect stimulatory effect on antioxidant enzymes including
GR, SOD, GSH-Px and CAT.[76–80] Additionally, melatonin
enhances MnSOD expression, which causes a reduction in
ROS concentration.[56] Melatonin was recognized as an
inhibitor of the ubiquitin-proteasome system.[81] Mela-
tonin modulates its non-enzymatic and enzymatic antioxi-
dants property due to modification of antioxidant enzyme
gene expression and inactivation of nuclear ROR-alpha
melatonin receptor through reaction with calmodulin.[51]
Furthermore, melatonin with its strong antioxidant effects
on ovarian follicles has effects in growing fetus, maturating
oocyte, reducing the oxidative stress during ovulation,
decreasing number of mature atrophied follicles and
preserving structures such as theca follicular and
zonapellucida.[57]
Anti-apoptotic effects of melatonin
Apoptosis is a regulated form of cell death which is neces-
sary for survival and homoeostasis in multicellular life
forms. Physiologically, apoptosis decreases transformed or
harmed cells and requires to control cell numbers, organ
and tissue morphology. Any irregularity in apoptosis
process often results in cancer and tissue disorders.[43]
Melatonin supplementation promotes the efficiency of
murine-induced pluripotent stem cells production via the
inhibition of p53 in apoptosis pathway.[82] As a result, p53
is a significant protein related to the effects of melatonin
and busulfan. However, melatonin reduces the concentra-
tion of p53 because of enhancing the SIRT1 expression.[56]
Melatonin improved histopathological changes and apop-
tosis via the unfolded protein response in testes and inhibi-
tion of endoplasmic reticulum stress.[83,84] Nuclear
FOXO3a is needed for keeping quiescence of the primordial
follicles. After phosphorylation of FOXO3a and PTEN, they
are translocated to the cytoplasm during follicle activation.
Cisplatin or melatonin did not affect FOXO3a expression.
However, cisplatin can induce an increase in FOXO3a and
PTEN phosphorylation. Melatonin downregulates phos-
phorylation of FOXO3a and PTEN.[45] Thus, melatonin
reduced cisplatin-induced exhaustion of primordial follicle
in the ovary mainly via phosphorylation and activation of
PTEN/AKT/FOXO3a pathway.[45]
Antiproliferative effects of melatonin
It has been reported that the increment of proliferating cell
nuclear antigen in testicular germ cells demonstrate high
proliferative and stimulation of spermatogenesis.[85] It
seems that mitotic proliferation of germ cells is dependent
on the c-kit system, stem cell factor,[86] GnRH[86–89] and
estradiol concentrations.[90,91] Furthermore, melatonin can
decrease the damage effects of busulfan through the two
procedures. Firstly, it reduces the release of LH and FSH
via the direct effect on hypothalamic–pituitary–gonadal
axis and secondly, it has a positive effect through an indi-
rect antiproliferative effect on the germ cells and other cells.
In a study by Hermann et al.,[92] it is reported that mela-
tonin has antiproliferative effects on mouse hepatoma cell
line. In another study, Bartsch et al.[93] indicated that
melatonin has an inhibitory effect on ovarian carcinoma in
individual patients.
Effects of melatonin on sexual hormones
and receptor-mediated
Melatonin and the sex hormones are interrelated under
both pathological and physiological conditions. Che-
motherapeutic drugs can alter sexual hormone levels and
co-administration of melatonin effects these alterations.
The increment of testosterone level is consistent with
protection effect of melatonin on Leydig cells; because of
existence of melatonin binding sites in the reproductive
system.[55] It also may be due to the direct effect of mela-
tonin on the steroidogenic cells of the reproductive sys-
tems.[94] In another study, it has been shown that
increasing testosterone levels, due to melatonin effect on
Leydig cells, maybe because of the coupling melatonin
receptors via pertussis toxin-sensitive G-protein in Leydig
cells.[95] Interestingly, there is an inverse relationship
between GnRH receptors and melatonin in mice, thus, it
directly controls the ovarian activity and reduces secre-
tion of LH and FSH.[96] Additionally, melatonin can alter
the function of the hypothalamic–pituitary–gonadal axis
via its ability to change the secretion of GnRH through
its binding sites in the suprachiasmatic nucleus, hypotha-
lamic premammillary or mediobasal hypothalamus
region.[97]
Besides binding sites of melatonin recognized in the vari-
ous parts of the reproductive organs, it can assume that
melatonin also handles its functions not only as an antioxi-
dant but also via direct reaction with its receptors on the
steroidogenic cells.[94] According to melatonin receptors
detected on the epididymis and low affinity in binding sites
of melatonin identified in spermatozoa, it is feasible that
melatonin impresses sperm mobility as they pass via the
epididymis.[98]
Chemosensitizing effects of melatonin
It has been shown that melatonin meaningfully enhanced
the cytotoxic effect of some chemotherapy drugs. For
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instance, in a study, melatonin synergistically prevented cis-
platin-induced apoptosis through the phosphorylation of
ERK association with HSP27 and dephosphorylation
p90RSK in SK-OV-3 cells.[61] In addition, melatonin signif-
icantly blocked the colocalization and expression of HSP27
and p90RSK by combination treatment with cisplatin.[61]
As a result, they suggested that melatonin can be useful in
combination with cisplatin to ameliorate the therapeutic
effect of cisplatin for treatment of ovarian cancer by target-
ing the ERK/p90RSK/HSP27 pathway. Moreover, mela-
tonin with cisplatin meaningfully enhanced the ratio of
cells going in mitochondrial apoptosis because of ROS
overproduction and substantially augmented DNA frag-
mentation in comparison with cisplatin group in HeLa
cells.[60] Recently, several studies showed that melatonin
may have a pro-oxidant effect through endoperox-
ides molecules arisen or NF-kB activation in tumour
cells.[99–101] As a result, synergistic antitumour functions
related to melatonin are still debatable. It may be depen-
dent on the tissue where malignant cells arose from it and
the applied chemotherapeutic drugs.[60]
However, melatonin may reduce the efficacy of
chemotherapy based on several chemotherapeutic drugs,
many studies have demonstrated that non-protein thiols
and intracellular glutathione increased by melatonin due to
suppressing platinum, which may lead to resistance to cis-
platin chemotherapy.[102,103] Also, Ilbey et al.[37] observed
that rats receiving cisplatin or cyclophosphamide with
melatonin had less body weight loss, which is assumed to
be as one side effect of these chemotherapy drugs. Also, in a
study, co-administration of melatonin and doxorubicin did
not alter MDA and GST level and GR as well as SOD activ-
ity compared to doxorubicin group.[49] Chen et al.[104]
reported that melatonin induces apoptosis in germ cells.
So, it was concluded that melatonin effect on the cells is
dose- and time-dependent.[105] Racial differences can be a
factor for difference in the inherent sensitivity of germ cells
to the apoptosis. For example, it has been reported that the
incidence of spermatid and spermatogonial programed cell
death in Chinese males is more than Caucasian males.[106]
However, the exact mechanisms of melatonin effect on the
germ cells are not known. In a previous study in association
with antiproliferative effects of melatonin, it did not effect
on hepatoma cell lines of hamster but observed antiprolif-
erative properties on in-vivo condition.[107] Also, Ozdemir
et al.[108] did not find melatonin’s antiproliferative proper-
ties on hepatoma cell line of a human. The race of animals,
treatment time and the melatonin dose can be effective on
the proliferative property of melatonin. In an apoptosis
analysis, it has been indicated that melatonin cannot
improve busulfan-induced apoptosis. Given that cancer
cells have various ROS generation, tolerance and elimina-
tion mechanisms compared with normal cells.[56] In
association with the chemosensitizing effect of melatonin,
it has been reported that melatonin reduces the antitumour
effect of cisplatin in human liver carcinoma cells through
the adjustment of the balance of apoptotic proteins.[109]
Other reports have shown that melatonin does not partici-
pate with the cytotoxic effect of chemotherapeutic drugs
like daunorubicin, cytarabine and etoposide in various leu-
kaemia cell lines, consisting of MOLT-4, Daudi, Jurkat,
HL-60, K562 and CMK.[110] Kim et al.[61] showed that
melatonin does not have an effect on levels of phosphor
p90RSK and ERK1/2 in ovarian cancer cells; as they showed
that co-administration cisplatin and melatonin sensitize the
inhibition of phospho-ERK1/2 and p90RSK compared with
cisplatin alone.
Perspective of future research of melatonin
Cancer is one of a major condition which affects every soci-
ety in the world. Cancer incident is varying by age, sex, per-
sonal and personal life condition, racial and ethnic group,
geographic location and other categories.[1,111] In this con-
tent, the most common cancer is related to the non-repro-
ductive system. Although the chemotherapy process is a
most effective cure for cancer, the side effect is high because
of effects on non-selective and harms to normal cells beside
cancer cells.[112] The reproductive system because of its’
multiorgan and polyunsaturated fatty acids nature as well
as gonadotropin hormones are very vulnerable to toxicity
induced by chemotropic drugs.[113,114] Therefore, the
researchers are trying to find an effective way to reduce
harms to the reproductive system. One of the proposed
approaches is co-administration with non-chemotropic
drugs which reduce harms to normal cell and multiplier
effects of these agents in cancer cells. According to our
study, melatonin reduces oxidative stress, apoptosis,
inflammation and modulates mitochondrial func-
tion.[12,14,15,18,19,27] Also, it can block pathway which leads
to reducing harms to normal cells during chemotherapy
process in reproductive or non-reproductive cancer, and
multiplier pathway related to the increased death of cancer
cell by chemotropic drugs. These facts support the previous
studies that demonstrate the effects of melatonin in reduc-
ing side effects of chemotropic drugs in the reproductive
system.[32,37,39,43–45,48,49,51,53,55–57,64] Furthermore, mela-
tonin has a sensitizing role the reproductive cancer
cells.[60,61] In this content, melatonin presents several direct
and indirect properties including antioxidant, anti-inflam-
matory, anti-apoptotic, mitochondrial protection and
antidepressant property, besides its low toxicity. Consider-
ing all of these results, we propose that more researches are
needed and melatonin is an attractive pharmacological can-
didate for combination therapy with chemotropic drugs in
clinical trials because it reduces harmful effect in the
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reproductive system in vulnerable people during
chemotherapy process and enhances the effect of chemo-
tropic drugs to kill cancer cells in the reproductive system.
Conclusion
Chemotherapeutic drugs exert harmful effects on the
reproductive system through several pathways. In
chemotherapy process, oxidative stress, apoptosis, tissue
injury, mitochondrial malfunctions and sexual hormones
alteration will rise in normal cells of reproductive system
which causes fecundity reduction. Furthermore,
chemotherapeutic drugs have deleterious effects on repro-
ductive organs, follicles, ovary and sperm quality and
quantity as well as sexual hormones. The low toxicity of
melatonin consumption even in high dosage and its cyto-
protective effects through several mechanisms bring posi-
tive effects in the reproductive system. Melatonin directly
through free radicals scavenging and indirectly through
modulating antioxidant enzymes reduces oxidative stress.
Moreover, melatonin with its anti-apoptotic effects,
including inhibition of caspase-3 activation, PARP cleav-
age and modulating mitochondrial function, reduces
apoptosis. In addition, melatonin ameliorates reproduc-
tive injury through modulating sexual hormones and
antiproliferative effect alongside receptors-mediated prop-
erties in reproductive organs. In other hand, it is shown
that melatonin has sensitizing effects in cancer cells.
Melatonin in combination with chemotherapeutic drugs
increases oxidative stress. Also, melatonin increases apop-
tosis through enhancement of caspase-3 and 9 activity,
cleavage of PARP and dephosphorylation of PTEN/AKT/
FOXO3a pathway. Taking together, melatonin with its
bilateral role can protect the reproductive system during
chemotherapy process in both normal and cancer cells.
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